NervGen Pharma Grants Stock Options
NervGen Pharma (OTCQB: NGENF), a clinical-stage biotech company focused on neuroreparative therapeutics, has announced the granting of 600,000 incentive stock options. The options are structured as follows:
- 500,000 options granted to Directors, exercisable at $4.00 per share for 5 years, vesting quarterly over 1 year
- 100,000 options granted to employees, exercisable at $4.00 per share for 10 years, vesting semi-annually over 4 years
All options comply with TSX Venture Exchange policies and the company's stock option plan.
NervGen Pharma (OTCQB: NGENF), un'azienda biotecnologica in fase clinica specializzata in terapie neuro-riparatrici, ha annunciato la concessione di 600.000 opzioni azionarie incentivanti. Le opzioni sono strutturate come segue:
- 500.000 opzioni assegnate ai Direttori, esercitabili a 4,00 $ per azione per 5 anni, con maturazione trimestrale in un periodo di 1 anno
- 100.000 opzioni assegnate ai dipendenti, esercitabili a 4,00 $ per azione per 10 anni, con maturazione semestrale in un periodo di 4 anni
Tutte le opzioni sono conformi alle politiche della TSX Venture Exchange e al piano di opzioni azionarie della società.
NervGen Pharma (OTCQB: NGENF), una empresa biotecnológica en fase clínica centrada en terapias neuroreparadoras, ha anunciado la concesión de 600,000 opciones de acciones incentivadas. Las opciones están estructuradas de la siguiente manera:
- 500,000 opciones otorgadas a los Directores, ejercitables a $4.00 por acción durante 5 años, con consolidación trimestral a lo largo de 1 año
- 100,000 opciones otorgadas a empleados, ejercitables a $4.00 por acción durante 10 años, con consolidación semestral a lo largo de 4 años
Todas las opciones cumplen con las políticas de la Bolsa de Valores TSX Venture y el plan de opciones sobre acciones de la compañía.
NervGen Pharma (OTCQB: NGENF)는 신경 재생 치료제에 중점을 둔 임상 단계 바이오텍 회사로서 600,000개의 인센티브 스톡 옵션 부여를 발표했습니다. 옵션 구성은 다음과 같습니다:
- 이사들에게 부여된 500,000 옵션, 주당 행사 가격 $4.00, 5년간 유효하며 1년 동안 분기별로 권리 취득
- 직원들에게 부여된 100,000 옵션, 주당 행사 가격 $4.00, 10년간 유효하며 4년 동안 반기별로 권리 취득
모든 옵션은 TSX 벤처 거래소 정책과 회사의 스톡 옵션 계획을 준수합니다.
NervGen Pharma (OTCQB : NGENF), une société biotechnologique en phase clinique spécialisée dans les thérapies neuro-réparatrices, a annoncé l'attribution de 600 000 options d'achat d'actions incitatives. Les options sont structurées comme suit :
- 500 000 options attribuées aux administrateurs, exerçables à 4,00 $ par action pendant 5 ans, avec acquisition trimestrielle sur 1 an
- 100 000 options attribuées aux employés, exerçables à 4,00 $ par action pendant 10 ans, avec acquisition semestrielle sur 4 ans
Toutes les options sont conformes aux politiques de la TSX Venture Exchange et au plan d'options d'achat d'actions de la société.
NervGen Pharma (OTCQB: NGENF), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das sich auf neuroregenerative Therapien spezialisiert hat, hat die Gewährung von 600.000 Anreiz-Aktienoptionen bekannt gegeben. Die Optionen sind wie folgt strukturiert:
- 500.000 Optionen wurden an Direktoren vergeben, ausübbar zu je 4,00 $ pro Aktie für 5 Jahre, mit vierteljährlicher Vesting über 1 Jahr
- 100.000 Optionen wurden an Mitarbeiter vergeben, ausübbar zu je 4,00 $ pro Aktie für 10 Jahre, mit halbjährlicher Vesting über 4 Jahre
Alle Optionen entsprechen den Richtlinien der TSX Venture Exchange und dem Aktienoptionsplan des Unternehmens.
- None.
- None.
Vancouver, British Columbia--(Newsfile Corp. - May 16, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotechnology company dedicated to developing neuroreparative therapeutics, today announced that it has granted 600,000 incentive stock options (the "Options") to directors and employees of the company. The Options are exercisable at a price of
About NervGen
NervGen (TSXV: NGEN) (OTCQB: NGENF) is a clinical-stage biotech company dedicated to developing innovative treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company is testing the clinical efficacy of its lead candidate, NVG-291, in a Phase 1b/2a clinical trial in spinal cord injury and has initiated preclinical test of concept evaluation of our pipeline candidate, NVG-300, in models of ischemic stroke and spinal cord injury. For more information, visit www.nervgen.com and follow NervGen on X and LinkedIn for the latest news on the company.
Contacts
Huitt Tracey, Investor Relations
htracey@nervgen.com
604.537.2094
Bill Adams, Chief Financial Officer
info@nervgen.com
778.731.1711
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/252471
FAQ
What is the exercise price of NGENF's newly granted stock options?
How many stock options did NervGen Pharma (NGENF) grant to directors in May 2025?
What is the vesting schedule for NGENF's employee stock options granted in May 2025?
What is the expiration period for the stock options granted by NGENF to directors and employees?
